Evidence map›Paper›PMID 41656299›Full record

ArticleNature communications2026

Uncovering Cas9 PAM diversity through metagenomic mining and machine learning.

Tao Fang, Lea Bogensperger, Lilith Feer, Ahmed Allam, Valentyn Bezshapkin, Zsolt Balázs, Christian von Mering, Shinichi Sunagawa, Michael Krauthammer, Gerald Schwank

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tao Fang *Institute of Pharmacology and Toxicology, University of Zurich, Zürich, Switzerland.
Lea Bogensperger *Department of Quantitative Biomedicine, University of Zurich, Zürich, Switzerland.
Lilith FeerDepartment of Quantitative Biomedicine, University of Zurich, Zürich, Switzerland.
Ahmed AllamDepartment of Quantitative Biomedicine, University of Zurich, Zürich, Switzerland.ORCID 0000-0003-0871-1977
Valentyn BezshapkinInstitute of Microbiology, ETH Zurich, Zürich, Switzerland.
Zsolt BalázsDepartment of Quantitative Biomedicine, University of Zurich, Zürich, Switzerland.ORCID 0000-0003-3537-7441
Christian von MeringDepartment of Molecular Life Sciences, University of Zurich, Zürich, Switzerland.
Shinichi SunagawaInstitute of Microbiology, ETH Zurich, Zürich, Switzerland.ORCID 0000-0003-3065-0314
Michael KrauthammerDepartment of Quantitative Biomedicine, University of Zurich, Zürich, Switzerland. michael.krauthammer@usz.ch.ORCID 0000-0002-4808-1845
Gerald SchwankInstitute of Pharmacology and Toxicology, University of Zurich, Zürich, Switzerland. schwank@pharma.uzh.ch.ORCID 0000-0003-0767-2953

Funding

European Research CouncilSNSFSwiss National Science Foundation (SNSF)
6 · The paper itself

Abstract

Recognition of protospacer adjacent motifs (PAMs) is crucial for target site recognition by CRISPR-Cas systems. In genome editing applications, the requirement for specific PAM sequences at the target locus imposes substantial constraints, driving efforts to search for novel Cas9 orthologs with extended or alternative PAM compatibilities. Here, we present CRISPR-PAMdb, a comprehensive and publicly accessible database compiling Cas9 protein sequences from 3.8 million bacterial and archaeal genomes and PAM profiles from 7.4 million phage and plasmid sequences. Through spacer-protospacer alignment, we infer consensus PAM preferences for 8003 unique Cas9 clusters. To extend PAM discovery beyond traditional alignment-based approaches, we develop CICERO, a machine learning model predicting PAM preferences directly from Cas9 protein sequences. Built on the ESM2 protein language model and trained on the CRISPR-PAMdb database, CICERO achieves an average cosine similarity of 0.69 on test data and 0.75 on experimentally validated Cas9 orthologs. For Cas9 clusters where alignment-based predictions are infeasible, CICERO generates PAM profiles for an additional 50,308 Cas9 proteins, including 17,453 high-confidence predictions with CICERO confidence scores above 0.8. Together, CRISPR-PAMdb and CICERO enable large-scale exploration of PAM diversity across Cas9 proteins, accelerating design of next-generation CRISPR-Cas9 tools for precise genome engineering.

Indexed as

CRISPR-Cas SystemsMachine LearningMetagenomicsNucleotide MotifsArchaeaBacteriophagesDatabases, GeneticData MiningGenome, ArchaealGenome, Bacterial

Identifiers

PMID41656299
PMCPMC12996302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.